We present a successful case of the use of a HeartWare ventricular assist device as a bridge to transplantation in an 11-year-old with a hypoplastic left heart and failed Fontan circulation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.athoracsur.2013.11.075 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Subaortic pannus causing complete outlet obstruction after bioprosthetic aortic valve replacement in a patient with left ventricular assist device: a case report.
Eur Heart J Case Rep
December 2024
Heart and Lung Transplant Unit, St Vincent's Hospital, Darlinghurst, Sydney, NSW 2010, Australia.
Background: Subaortic pannus formation complicates bioprosthetic aortic valve (AV) replacement. We report an extreme case in a continuous-flow left ventricular assist device (LVAD) patient.
Case Summary: A 49-year-old Caucasian female with dilated cardiomyopathy was bridged to transplant with a HeartWare Ventricular Assist Device (Medtronic).
Impact of concomitant aortic valve replacement in patients with mild-to-moderate aortic valve regurgitation undergoing left ventricular assist device implantation: EUROMACS analysis.
Artif Organs
December 2024
City of Health and Science Hospital Turin, Department of Surgical Sciences, University of Turin, Turin, Italy.
Introduction: Left ventricular assist device (LVAD) therapy may lead to an aortic regurgitation, limiting left ventricular unloading and causing adverse events. Whether concomitant aortic valve replacement may improve outcomes in patients with preoperative mild-to-moderate aortic regurgitation remains unclear.
Methods: A retrospective propensity score-matched analysis of adult patients with preoperative mild-to-moderate aortic regurgitation undergoing durable LVAD implantation between 01/01/2011 and 30/11/2021 was performed.
Treating Older Patients in Cardiogenic Shock With a Microaxial Flow Pump: Is It DANGERous?
J Am Coll Cardiol
November 2024
Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark; Department of Cardiology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern, Odense, Denmark. Electronic address:
Article Synopsis
- This study examines how age influences the effectiveness of microaxial flow pump (mAFP) treatment for patients suffering from ST-elevation myocardial infarction (STEMI) and cardiogenic shock (CS), using data from the DanGer Shock trial involving 355 participants.
- Findings reveal that mortality rates significantly increase with age, from 31% in the youngest group to 73% in the oldest, showing younger patients (<77 years) benefit more from mAFP treatment (lower mortality), while older patients (≥77 years) do not have the same advantage.
- The study also notes that complications were more common in the mAFP group, but overall, age significantly impacted survival outcomes, highlighting
Durable left ventricular assist devices following temporary circulatory support on a microaxial flow pump with and without extracorporeal life support.
JTCVS Open
October 2024
Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum der Charité, Berlin, Germany.
Background: Circulatory support with a catheter-based microaxial flow pump (mAFP) plays a major role in the treatment of severe cardiogenic shock. In most patients who fail to recover while on temporary mechanical circulatory support (tMCS) and who are not eligible for heart transplantation, durable left ventricular assist device (dLVAD) implantation is usually considered a reliable option. This study aimed to describe the outcome of dLVAD therapy following mAFP support and to identify predictors of mortality.
View Article and Find Full Text PDFAcute Heart Failure With Unilateral Pulmonary Edema Due to Aortic Insufficiency During LVAD Support.
JACC Case Rep
October 2024
Montefiore-Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
Article Synopsis
- * A case study of a 47-year-old woman with a HeartWare left ventricular assist device (LVAD) highlighted how she experienced UPE linked to inadequate heart function, but after adjusting the LVAD speed, her symptoms improved.
- * Recognizing UPE quickly is essential, as it can significantly increase mortality risk due to potential misdiagnosis and delays in effective treatment, especially in patients using LVADs for severe heart failure.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!